ArticleDrugs - real world outcomes2024

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry.

Mark Lebwohl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.